An article distributed by Bloomberg News on a new drug for treating psoriasis that appears to deliver better results and is easier to take, but has not been cleared by U.S. regulators, quotes Robert Kalb, clinical associate professor of dermatology. The article appeared in several newspapers, including the Chicago Tribune.